P4‐363: The medical food Souvenaid preserves functional brain network organisation in patients with mild Alzheimer's disease

clinical evaluation was complex; but for our purpose we have used MMSE, grouping the patients into stages: mild (MMSE score 21-26), mild to moderate (MMSE score 15-20), moderate (MMSE score 10-14) and severe (MMSE score Below 10).For evaluating their socioeconomic and clinical status the Centre’s standard questionnaire was used; care costs were included (for medications, use of professional services, use of community support services by caregivers and lay carers.Caregiver burden was also determined by specific scales, using the human capital method. Descriptive statistics and regression models were used.Assessment of costs was made considering existing costs at 1st of January, 2010 as applicable to a discounting rate of 6%. Results: A total of 64 claims were reviewed. The average total cost of AD per patient per a 12-month period was ,V6072. The proportion of cost attributable to caregivers was the main component of burden 61% in AD.The annual societal cost of care per patient increased with severity of Alzheimer’s disease. The cost per patient was estimated to be 5.378V 8V for mild disease, 6.259V for mild to moderate disease, 6.343V for moderate disease and 6.407V for severe disease. Poorer functional status was associated with higher total and care giving costs. For subjects living in the community, unpaid caregiver time was the greatest components of cost and increased with disease severity. Conclusions: Health care costs for AD are substantial. The societal cost of care of Alzheimer’s disease increases with increasing disease severity. Informal cost is responsible for the largest cost component